Cardiff Oncology (CRDF) Moves 20.5% Higher: Will This Strength Last? [Yahoo! Finance]
Cardiff Oncology, Inc. (CRDF)
Company Research
Source: Yahoo! Finance
This compares to the stock's 169.9% gain over the past four weeks. The sudden rise in the stock price can be attributed to the positive investor mindset regarding the company's pipeline, which comprises only its lead candidate, onvansertib. Cardiff Oncology oncology is currently developing onvansertib in separate early to mid-stage studies to treat different cancer indications. This molecular diagnostic company is expected to post quarterly loss of $0.25 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $0.11 million, up 37.5% from the year-ago quarter. While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For Cardiff Oncology, the consensus EPS estimate for the quarter has been revised 14.7% higher over the last 30 days to the cu
Show less
Read more
Impact Snapshot
Event Time:
CRDF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRDF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRDF alerts
High impacting Cardiff Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
CRDF
News
- Cardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateGlobeNewswire
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study [Yahoo! Finance]Yahoo! Finance
- Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyGlobeNewswire
- Cardiff Oncology (CRDF) Is a Great Choice for 'Trend' Investors, Here's Why [Yahoo! Finance]Yahoo! Finance
- Here's Why Momentum in Cardiff Oncology (CRDF) Should Keep going [Yahoo! Finance]Yahoo! Finance
CRDF
Earnings
- 11/2/23 - Beat
CRDF
Sec Filings
- 4/25/24 - Form DEFA14A
- 4/25/24 - Form ARS
- 4/25/24 - Form DEF
- CRDF's page on the SEC website